



(11) **EP 3 149 039 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07K 16/26** <sup>(2006.01)</sup> **A61K 33/24** <sup>(2019.01)</sup>  
**A61K 39/395** <sup>(2006.01)</sup> **A61K 39/00** <sup>(2006.01)</sup>  
**A61K 45/06** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**01.04.2020 Bulletin 2020/14**

(86) International application number:  
**PCT/EP2015/062168**

(45) Date of publication and mention of the grant of the patent:  
**12.02.2020 Bulletin 2020/07**

(87) International publication number:  
**WO 2015/185513 (10.12.2015 Gazette 2015/49)**

(21) Application number: **15729772.2**

(22) Date of filing: **01.06.2015**

(54) **ANTI-NEUROTENSIN ANTIBODIES AND USES THEREOF**

ANTI-NEUROTENSIN-ANTIKÖRPER UND VERWENDUNGEN DAVON

ANTICORPS ANTI-NEUROTENSINE ET LEURS UTILISATIONS

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(30) Priority: **02.06.2014 EP 14305825**

(43) Date of publication of application:  
**05.04.2017 Bulletin 2017/14**

(73) Proprietors:  
• **INSERM (Institut National de la Santé et de la Recherche Médicale)**  
**75013 Paris (FR)**  
• **Université de Paris**  
**75006 Paris 6 (FR)**

(72) Inventor: **FORGEZ, Patricia**  
**F-75270 Paris Cedex 06 (FR)**

(74) Representative: **Inserm Transfert**  
**7, rue Watt**  
**75013 Paris (FR)**

(56) References cited:  
**WO-A1-2010/069929**

- **WINKLER K ET AL: "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505-4514, XP002579393, ISSN: 0022-1767**
- **MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285-3291, XP002649029, ISSN: 0022-1767**
- **MAYNARD JENNIFER A ET AL: "Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 20, no. 6, 1 June 2002 (2002-06-01), pages 597-601, XP002390004, ISSN: 1087-0156, DOI: 10.1038/NBT0602-597**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 149 039 B8**

- **BARDERAS RODRIGO ET AL:** "Affinity maturation of antibodies assisted by in silico modeling", **PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US**, vol. 105, no. 26, 1 July 2008 (2008-07-01) , pages 9029-9034, XP002592575, ISSN: 0027-8424, DOI: 10.1073/PNAS.0801221105 [retrieved on 2008-06-23]
- **RAIEES ANDRABI ET AL:** "Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals", **VIROLOGY**, vol. 439, no. 2, 1 May 2013 (2013-05-01), pages 81-88, XP055093156, ISSN: 0042-6822, DOI: 10.1016/j.virol.2012.12.010
- **CARRAWAY R E ET AL:** "Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools", **PEPTIDES, ELSEVIER, AMSTERDAM, NL**, vol. 27, no. 10, 1 October 2006 (2006-10-01), pages 2445-2460, XP027957619, ISSN: 0196-9781 [retrieved on 2006-10-01]